- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | Relief Therapeutics Holding SA - 6-K, Report of foreign issuer | 8 | SEC Filings | ||
| 11.11. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa | 3.504 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Study results
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
11-Nov-2024 / 07:00... ► Artikel lesen | |
| 05.11. | Relief Therapeutics Holding SA - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 04.11. | Relief Therapeutics unterzeichnet Absichtserklärung für Zusammenschluss mit Renexxion | 29 | cash | ||
| 04.11. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger | 2.506 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Merger
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
04-Nov-2024 / 07:00 CET/CEST
Release of an... ► Artikel lesen | |
| 29.10. | Relief Therapeutics Holding SA: Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE | 269 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Miscellaneous
Relief Therapeutics Announces Publication of Plain Language Summary on PKU GOLIKE
29.10.2024 / 07:00 CET/CEST
Relief... ► Artikel lesen | |
| 25.10. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents | 4.447 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Study results
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents
25-Oct-2024 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| 22.10. | Relief Therapeutics Holding SA - 6-K, Report of foreign issuer | 8 | SEC Filings | ||
| RELIEF THERAPEUTICS HOLDING AG ADR Aktie jetzt für 0€ handeln | |||||
| 21.10. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment | 2.827 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Patent
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
21-Oct-2024... ► Artikel lesen | |
| 09.10. | Relief Therapeutics Holding SA - 6-K, Report of foreign issuer | 24 | SEC Filings | ||
| 08.10. | Relief Therapeutics gains on proof-of-concept data for antimicrobial agent | 31 | Seeking Alpha | ||
| 08.10. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa | 3.308 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Study results
Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
08-Oct-2024... ► Artikel lesen | |
| 04.10. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria | 6.456 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Study results
Relief Therapeutics Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria
04-Oct-2024 /... ► Artikel lesen | |
| 23.09. | Relief Therapeutics Receives $2M Milestone Payment Following FDA Approval | 10 | Contract Pharma | ||
| 23.09. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement | 3.111 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Miscellaneous
Relief Therapeutics Announces $2 Million Milestone Under Royalty Sales Agreement
23-Sep-2024 / 07:00 CET/CEST
Release of an... ► Artikel lesen | |
| 19.09. | Relief Therapeutics Holding SA - 6-K, Report of foreign issuer | 21 | SEC Filings | ||
| 18.09. | Relief Therapeutics Holding SA: Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 | 500 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Study
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024... ► Artikel lesen | |
| 02.09. | Relief Therapeutics Holding SA: Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 | 526 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Study
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
02.09.2024 / 07:00 CET/CEST
Relief... ► Artikel lesen | |
| 30.08. | Relief Therapeutics Holding SA - 6-K, Report of foreign issuer | 11 | SEC Filings | ||
| 30.08. | Relief Therapeutics reports 1H results | 3 | Seeking Alpha |
Seite:
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| REVIVE THERAPEUTICS | 0,001 | -91,67 % | Revive Therapeutics Ltd.: Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections | TORONTO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| EVOTEC | 8,500 | -15,59 % | Aktien KW 46 Trump-Verdauen. Neue Favoriten, Quartalsergebnisse - Gemengelage mit Licht und Schatten. Dazu Hoffen auf Jahresendrallye? News. Rheinmetall. Evotec. JDC. Mutares. Grammer. Hypoport. tonies. HomeToGo | Aktien Wochenrückblick - Fokus auf die "erwarteten" Folgen einer Präsidentschaft Trumps: Krypto's feiern neue Rekorde, China wird kritischer beäugt, wegen der bisher eher zögerlichen Konjunkturspritzen... ► Artikel lesen | |
| QIAGEN | 41,045 | +2,05 % | Qiagen NV-Aktie büßt 0,31 Prozent ein (39,06 €) | Im Minus liegt zur Stunde der Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 39,06 Euro. An der Börse liegt die Qiagen NV-Aktie aktuell im Minus. Das Papier verbilligte sich um 12 Cent. Das Wertpapier... ► Artikel lesen | |
| ARCELLX | 90,44 | +3,69 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| BIONTECH | 108,90 | +0,28 % | Kaufen oder Verkaufen?: Die spannende Zukunft von BioNTech, Pfizer & Co. | © Foto: SymbolbildAktien von BioNTech, Moderna und Pfizer geraten gerade ordentlich unter Druck - und das aus gutem Grund. Ex-Präsident Donald Trump hat einen überraschenden Schachzug gemacht, der die... ► Artikel lesen | |
| DYNE THERAPEUTICS | 29,690 | -0,27 % | Wissenschaftliche Leiterin von Dyne Therapeutics verkauft Aktien im Wert von 80.539 US-Dollar | ||
| KYMERA THERAPEUTICS | 44,980 | +3,38 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update | KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,695 | -0,96 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| KEROS THERAPEUTICS | 55,92 | +3,86 % | Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | ||
| MODERNA | 39,575 | +0,18 % | Opening Bell: Tech-Aktien am Montag im Plus; Tesla, Palantir, Moderna, Netflix, Nvidia im ... | Nach den jüngsten Kursausschlägen im Zuge des Wahlsiegs von Donald Trump steuern die US-Börsen am Montag auf einen relativ ruhigen Wochenstart zu. Während der Dow Jones Industrial vom Broker IG eine... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,79 | +0,01 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| VERA THERAPEUTICS | 48,290 | +2,68 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 18, 2024, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,160 | -0,66 % | Adma Biologics CEO Adam Grossman verkauft Aktien im Wert von 1,03 Millionen US-Dollar | ||
| SPRINGWORKS THERAPEUTICS | 39,030 | +7,52 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| 4D MOLECULAR THERAPEUTICS | 7,790 | -2,50 % | 4D Molecular initiated by Morgan Stanley at underweight |
RELIEF THERAPEUTICS HOLDING AG ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,107 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RELIEF THERAPEUTICS HOLDING AG ADR finden Sie auf Wallstreet Online.
